The Familial Mediterranean fever (FMF, MIM249100) is an autoimflammatory genetic disease characterized with recurrent painful attacks in the abdomen, chest or joints, usually accompanied with high body temperature. It is classically inherited in an autosomal recessive manner. It is associated with mutations of the MEFV gene, coding for the protein pyrin. More than 140 mutations of the MEFV gene are defined worldwide. Despite the progress in establishing reliable tests practical for routine use, as much as 20% of the patients with FMF remain without a detectable mutation in the MEFV gene. This is the main reason why the diagnosis of FMF remains still a clinical one, according to Tel Hashomer criteria.
Introduction
Familial Mediterranean fever (FMF, MIM249100) is a genetic multi-systemic disease with recurrent painful attacks in the abdomen, chest or joints as a main characteristic. Usually, the attacks are accompanied by high body temperature, and sometimes a skin rush. The disease was recognized as a separate entity in 1945 (Bakkaloglu, 2003) . Today, it is known under many names, such as recurrent hereditary polyserositis, benign paroxysmal peritonitis, periodical fever, periodical amyloid syndrome, Armenian syndrome or Reimann's periodical disease (Ben-Chetrit et al., 1998; Booth et al., 2000; Brik et al., 2001; Cazeneuve et al., 1999; Ryan et al., 2010) . Most frequently, this disease is found in people originating from the Mediterranean region (therefore the name), and classically it is most prevalent in four populations: Sephardi Jews (1/250-1000), Armenians (1/500), Turks (1/1000) and Arabs (1/2600). (Booth et al., 2000; Brik et al., 2001; Cazeneuve et al., 2000; Fujikura et al., 2015) . It is significantly less frequent in other populations. A vast number of patients with FMF (80-95%) are younger than 20 years at the time of diagnosis, while 50-60% of them are younger than 10 years (Dewalle et al., 1998; El-Shanti 2001) . Main complications associated with this disease are destructive oligoarthritis and secondary amyloidosis which could potentially lead to death (Gedalia 2004; Gershoni-Baruch et al., 2003; Gershoni-Baruch et al., 2002; Gershoni-Baruch et al., 2001 ).
The disease is classically inherited in an autosomal recessive manner. After identification of the gene responsible for the disease MEFV, in 1997, numerous studies have been conducted in order to examine the distribution of different MEFV mutations across populations and the different genotype-phenotype correlation Cazeneuve et al., 2000; Gershoni-Baruch et al., 2001; Kishida et al., 2014) . The MEFV gene is located on chromosome 13.3, and codes for a protein called pyrin or marenostrin, expressed only in neutrophils, serosal cells in the peritoneal and pleural spaces and in synovial cells (Haghighat et al., 2006; Kastner 1998) . The exact role of the protein is not yet known, but it was shown that it has certain effect on the control of the inflammation, probably through inhibition of C5a and Il-8 (Kubik et al., 2006) .
Case presentation
A 10 year old girl admitted to the Clinic of Pediatrics at the Faculty of Medicine in Skopje sub febrile, with stable vital parameters, pain in the left leg and discrete edema of the leg joints, accompanied with urticarial-like rash of the extremities. During her 13-day stay at the Clinic, repeated temperature rising up to 41 °C accompanied with fever and rash accentuation. Numerous laboratory tests and consultations with specialists were conducted. In absence of other obvious explanation for the fever, testing for FMF was requested. Presence of a heterozygous mutation E148Q was confirmed by genetic test.; the same detection was noted following father's DNA examination. The detection of the 12 most common MEFV mutations was performed using the commercial FMF StripA kit (ViennaL- Typical attacks are defined attacks of pain which last shortly (between 12 hours and 3 days), are recurrent (≥3 of same type) and accompanied with high body temperature (rectal temperature ≥38°C).
Incomplete attacks are defined attacks of pain similar to typical, except:
• Body temperature is not elevated; or • Attacks last longer or shorter compared to typical; • During the abdominal painful attacks, there is no sign of peritonitis.
• Abdominal attacks are localized; • The arthritis is localized in atypical joints. ab, VIenna, Austria), based on PCR and reverse hybridization technique. An informed consent was given prior to examination.
Management and outcome
According to the Tel Hashomer criteria (Table 1 ) (one major -monoarthritis, one minor -positive response to Colchicine, and five additional -age ≤ 20, severe attack, spontaneous remission, attack-free period, and occasional inflammatory episodes with abnormal (high) leukocyte count and/or ESR), a diagnosis of FMF was assigned. The therapy of choice, colchicine, was prescribed orally in a dose of 1.5 mg/day, which lead to complete resolution of the symptoms following two days of treatment.
Discussion
In reviewing the spectrum and the penetrance of different mutations of the MEFV gene, it seems that three mutation hotspots are identified, namely codons 148, 680, and 694. A total of more than 140 mutations of the MEFV gene are by now reported worldwide (Matzner et al., 1984) . However, it is evident only five of them are globally responsible for the majority (some 70%) of the FMF cases, namely mutations V726A, M694V, M694I, M680I and E148Q (Matzner et al., 1984; Pras et al., 1998; Mijatovic et al., 2003 , Mohammadnejad, 2013 . Despite the obvious progress in the last decade in establishing molecular tests convenient for routine use, as much as 20% of the patients with FMF remain without a detectable mutation in the MEFV gene and the diagnosis still relies on clinical criteria. Another important characteristic of the disease is the diversity of symptoms and their varying severity in different patients. Notably, this high heterogeneity is not always in parallel with the type of the mutation, although some mutations are believed to confer a more severe presentation (726, 694) whereas some other a less severe one (148) i.e. the clinical presentation of certain genotypes in homozygous, heterozygous or combined heterozygous patients (Jéruet al 2013; Shohat et al., 1999; Shinawi et al., 2000; Tchernitchko et al., 2003 Touitu, 2001 ). This points out to potential modifying factors, such as gender, MEFV and other modifying mutations. Obviously, other, not yet identified population factors that influence the clinical manifestation of the disease cannot be excluded.
Although the disease is classically inherited in a recessive manner, some atypical cases of autosomal dominant inheritance are described. This finding was confirmed in two separate families, one with Ashkenazi, and the other with Georgian origin. By following the FMF in 4 successive generations of family members, it was confirmed that in both cases the underlying mutation responsible for the unusual inheritance was E148Q (OMIM 607108.0005), present in heterozygous state. Again however, the role of other not as-yet identified pyrin gene mutations cannot be excluded.
Our patient may be another case supporting the unusual dominant inheritance, since the heterozygous state for the E148Q mutation was the only positive finding in the genotyping of the 12 most frequent MEFV mutations. It would be interesting to perform DNA sequencing of the entire MEFV gene in this patient (we are currently arranging it), in order to exclude possibly present genetic deviations other than the twelve mutations analyzed.
